Collectively, our data indicate that PITPNA-AS1 exerts tumor-promoting effects in HCC progression and that PITPNA-AS1/miR-363- 5p/PDGFD axis may be a good pharmaceutical target for HCC treatment. This evidence concerns the gene PITPNA and hepatocellular carcinoma.